Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration

 Regeneron and Geisinger Health System Announce Major Human Genetics Research
                                Collaboration

This initiative combines world-class clinical care and premier scientific
research with the aim of improving patient care and accelerating innovation in
drug discovery and development

PR Newswire

TARRYTOWN, N.Y., Jan. 13, 2014

TARRYTOWN, N.Y., Jan. 13, 2014 /PRNewswire/ --Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) and Geisinger Health System (Geisinger), one of the largest
integrated health systems in the United States serving approximately 3 million
residents, today announced a major research collaboration focused on studying
the genetic determinants of human disease.

Beginning only ten years after the sequence of the first complete human genome
was published, this new research collaboration will include one of the largest
United States populations of participants for the analysis and sequencing of
genetic material and comparison to long-term health outcomes.

During the initial five-year collaboration term, Geisinger plans to collect
samples from more than 100,000 consented patient volunteers, while Regeneron,
through its wholly-owned subsidiary, Regeneron Genetics Center LLC, will
perform sequencing and genotyping to generate de-identified genomic data. The
size and scope of the study are meant to allow great precision in identifying
and validating the associations between genes and human disease.

"For Geisinger, this relationship is about the potential to improve
individualized patient care," commented David H. Ledbetter, Ph.D., Executive
Vice President and Chief Scientific Officer of Geisinger Health System. "We
expect that many of our patients will directly benefit from their
participation in this research because of Geisinger's ability to validate and
return clinically actionable results to them, and all of our patients will
benefit from the knowledge we gain in how to help set the standard for
genomically informed care. This collaboration has the potential to provide
Geisinger with tools to transform our ability to foresee disease before the
onset of symptoms, diagnose chronic and potentially fatal conditions before
it's too late to intervene, and determine how best to optimize the health and
well-being for each of our patients."

"Genetics has been at the core of our research efforts at Regeneron since its
early days," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer
and President, Regeneron Laboratories. "In fact, our first FDA-approved
therapy treats a rare genetic disorder, and the target of one of our product
candidates in late stage development that acts to lower LDL cholesterol was
identified using human genetics.^1 With the tremendous recent advances in DNA
sequencing, we believe that now is the time to increase our commitment to, and
investment in, human genetics research. We believe that Geisinger is the best
partner for addressing remaining limitations in making human genetic
discoveries, and our proprietary VelociGene® and VelocImmune® technologies
may provide the best way to advance these discoveries."

The collaboration will benefit from Geisinger's state of the art sample
collection and storage capabilities, the MyCode™ biorepository, and extensive
electronic medical records. Regeneron has built a team and an infrastructure
to support sequencing and genotyping over the term of the collaboration.
Regeneron intends to use its translational research and functional biology
capabilities, including its VelociGene® technology, to validate observed human
genetic associations.

"We are pleased to be embarking on this next generation human genetic
sequencing project with Geisinger, a renowned integrated health care delivery
system known for its innovation," said Leonard S. Schleifer, M.D., Ph.D.,
President and Chief Executive Officer of Regeneron.

"Research is a core part of Geisinger's mission, and there is no more
important medical research being done today than in genomics," added Glenn D.
Steele, Jr., M.D., Ph.D., President and Chief Executive Officer of Geisinger
Health System. "The combination of Geisinger and Regeneron brings together a
unique set of assets and expertise that allow us to conduct research of this
size and scope. I believe the long term benefits to human health and patient
care will be tremendous."

About The Regeneron-Geisinger Genetic Research Collaboration
Next-generation DNA sequencing technology is enabling genetic research on a
larger scale than ever before. The Regeneron-Geisinger Genomics Sequencing
Study is designed to leverage de-identified, clinical information and
molecular data for medically relevant associations in a blinded fashion that
preserves patients' privacy. The intent of the collaboration is to build a
high-throughput platform for discovering and validating genetic factors that
cause or influence a range of diseases where there are major unmet medical
needs. For Regeneron, this collaboration is the first step in a planned
expansion in the use of human genetics in the research process. For
Geisinger, this collaboration is meant to further its ongoing mission to
improve population health and individualized care through clinical innovation
and cutting edge, world-class research.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition, and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, asthma, and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.

About Geisinger Health System
Geisinger Health System is an integrated health services organization widely
recognized for its innovative use of the electronic health record and the
development of innovative care models such as ProvenHealth Navigator® and
ProvenCare® . As the nation's largest rural health services organization, GHS
serves more than 3 million residents throughout 44 counties in central and
northeastern Pennsylvania. The physician-led system is comprised of more than
20,800 employees, including a 1,100-member multi-specialty group practice,
seven hospital campuses, two research centers and a 448,000-member health
plan, all of which yield an estimated $6.1 billion positive impact on the
Pennsylvania economy. The health system and the health plan have repeatedly
garnered national accolades for integration, quality and service. In addition
to fulfilling its patient care mission, GHS has a long-standing commitment to
medical education, research and community service. For more information,
visit www.geisinger.org, or follow the latest GHS news and more on
TwitterandFacebook.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of
Regeneron, and actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs
now underway or planned including without limitation the planned genetic
research collaboration with Geisinger Health System, Regeneron's translational
research and functional biology capabilities, and the planned expansion in the
use of human genetics in Regeneron's research process; unforeseen safety
issues resulting from the administration of products and product candidates in
patients; the likelihood and timing of possible regulatory approval and
commercial launch of Regeneron's late-stage product candidates; ongoing
regulatory obligations and oversight impacting Regeneron's research and
clinical programs and business, including those relating to patient privacy;
determinations by regulatory and administrative governmental authorities which
may delay or restrict Regeneron's ability to continue to develop or
commercialize Regeneron's products and product candidates; competing drugs and
product candidates that may be superior to Regeneron's products and product
candidates; uncertainty of market acceptance and commercial success of
Regeneron's products and product candidates; the ability of Regeneron to
manufacture and manage supply chains for multiple products and product
candidates; coverage and reimbursement determinations by third-party payers,
including

Medicare and Medicaid; unanticipated expenses; the costs of developing,
producing, and selling products; the ability of Regeneron to meet any of its
sales or other financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential for any
license or collaboration agreement, including Regeneron's agreements with
Sanofi and Bayer HealthCare, to be cancelled or terminated without any further
product success; and risks associated with third party intellectual property
and pending or future litigation relating thereto. A more complete
description of these and other material risks can be found in Regeneron's
filings with the United States Securities and Exchange Commission, including
its Form 10-K for the year ended December 31, 2012 and its Form 10-Q for the
quarter ended September 30, 2013. The reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does not undertake
any obligation to update publicly any forward-looking statement, including
without limitation any financial projection or guidance, whether as a result
of new information, future events, or otherwise.

Your Investor Relations Contact at Regeneron:
Manisha Narasimhan, Ph.D. Tel. 914.847.5126
E-Mail: manisha.narasimhan@regeneron.com

Your Media Contact at Regeneron:
Peter Dworkin, Tel. 914.847.7640
E-Mail: peter.dworkin@regeneron.com

Your Media Contact at Geisinger Health System
Kathy Scullin, Chief Communications Officer
Cell: 610.888.5415
E-mail: kscullin@geisinger.edu

^1 Cohen JC. N Engl J Med 2006;354:1264-72

SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com
 
Press spacebar to pause and continue. Press esc to stop.